No Data
Express News | This week, more than 20 listed companies disclosed the repurchase and shareholding related information. Pingdingshan Tianan Coal Mining plans to repurchase special loans not exceeding 0.7 billion yuan.
Pharmaceutical Kangtian Biological (688046): Revenue grows steadily with short-term profit pressure.
Steady revenue growth, short-term profit pressure. In 2024 Q1-3, the company achieved revenue of 0.51 billion yuan (+12.1% year-on-year), and is expected to achieve steady growth in all business lines mainly due to the release of new domestic capacity and expansion of overseas markets.
Yakkang Biotech: Yakang Biotech Report for the Third Quarter of 2024
Yakkang Biotech Report for the Third Quarter of 2024
Yao Kang Biology (688046.SH): Achieved net income of 98.2144 million yuan in the first three quarters.
On October 30, Gelonhui announced that Pharmaron Biotech (688046.SH) released a statement, achieving revenue of 0.51 billion yuan in the first three quarters of 2024, an increase of 12.13% year-on-year; the net income attributable to shareholders of the listed company was 98.2144 million yuan, a decrease of 16.57% year-on-year, with basic earnings per share of 0.24 yuan.
Yaokang Biology (688046.SH): plans to spend 22 million yuan to -40 million yuan to buy back shares.
Great Wall News on October 30th, Yaoke Bio (688046.SH) announced that the company plans to repurchase some of the company's issued Renminbi ordinary shares (A-shares) through centralized competitive trading, with the repurchase amount not less than 22 million yuan (inclusive), and not more than 40 million yuan (inclusive); the repurchase share price does not exceed 18 yuan/share (inclusive).
No Data
No Data